This federal contract award, valued at $1,490.50, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Vyvanse 30 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This federal contract award, valued at $3,866.77, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Vyvanse 70 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a Firm Fixed Price Delivery Order, with an ultimate completion date of April 11, 2025. This award is not associated with a set-aside program and is...
This federal contract award, valued at $12,170.72, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Vyvanse capsules, a prescription medication used to treat Attention Deficit Hyperactivity Disorder (ADHD). The contract has a completion date of May 15, 2024 and is a Delivery Order under a larger Indefinite Delivery Contract (IDC) between...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,638.64 firm fixed-price delivery order is for the supply of Vyvanse 10 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract has an ultimate completion date of November 4, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC)...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $30,739.63 firm fixed-price contract is for the delivery of Vyvanse capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is not set aside and has an ultimate completion date of April 18, 2025. AmerisourceBergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery...
This federal contract award, valued at $3,710.99, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Vyvanse 40 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $3,148.38, is for the supply of Vyvanse 10 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a firm fixed-price, non-set-aside award with an ultimate completion date of April 17, 2025. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $19,848.26, is for the delivery of Vyvanse capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a Firm Fixed Price Delivery Order, with a completion date of November 6, 2023. This award is part of Amerisourcebergen's larger...
This federal contract award, valued at $4,441.47, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 10 mg capsules of the medication Vyvanse, a treatment for attention-deficit/hyperactivity disorder (ADHD). The contract has a firm fixed price and is set to expire on December 19, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,060.96, is a Delivery Order contract type with a Firm Fixed Price pricing structure. The contract is for the supply of Vyvanse 30 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract has an ultimate completion date of January 16, 2025 and was...